Assessing the Benefits of GLP-1 RAs
Improving Cardiac and Renal Well-being
GLP-1 RAs are injectable glucose-lowering medications approved by the FDA for the treatment of adult patients with T2DM. In addition, GLP-1 RAs have been identified as an important drug class for not only glucose-lowering but also in reducing cardiovascular disease (CVD) events in adults with T2DM and high atherosclerotic cardiovascular disease (ASCVD) risk.1
GLP-1 RAs stimulate glucose-dependent insulin release in the gut after food intake and inhibit glucagon release with concomitant decreased gastric emptying and low risk of hypoglycemia. Important secondary effects include a decrease in appetite and food intake, which can lead to weight loss of 2 to 4 kg, and improved lipid levels, with decreased triglyceride levels and increased high-density lipoprotein levels.
Game Changers – The game that invites you to test your knowledge of GLP-1 RAs
It's time to test your knowledge about GLP-1 RAs and their benefits as they relate to type 2 diabetes.
Categories range from diagnostic criteria to Lifestyle Management. Test your knowledge and find out with this fun, engaging game.
Vodcast Series
GLP-1 RAs: What You Need To Know
Practical Pointers to Optimize the Use of GLP-1 RAs
Conversation about the approved GLP-1 RAs to manage type 2 diabetes mellitus (T2DM). Forms of administration, contextualizing the many benefits and the risks, and indications will be discussed.
Claim CE Credit
Chronic Kidney Disease and GLP-1 RAs
Cardiovascular Benefits of GLP-1 RAs
Conversation around specific cardiovascular risks, while distinguishing between glycemic control and cardiovascular risk reduction. We will also highlight the benefits of treatment with GLP-1 RA in patients with diabetes.
Claim CE and MOC Credit
Demystifying GLP-1s
This activity focuses on the American Heart Association’s Essential 8 and glucose control. You will learn how GLP-1 RAs accelerate these glucose control goals and contribute to cardiorenal outcomes including how they work.
Claim CE and MOC Credit
Obesity and GLP-1 RAs
Conversation about the global rise of obesity and its association with diabetes and the limited effectiveness of many pharmacotherapies tested for management of obesity.
Claim CE Credit
Guidelines and Articles
- 2021 Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Hart Association/American Stroke Association | Stroke
- 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
- GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes | Circulation
- Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Assocation | Circulation